Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L (2019)
Publication Type: Journal article
Publication year: 2019
Book Volume: 41
Pages Range: 249-260
Journal Issue: 2
DOI: 10.1016/j.clinthera.2018.12.015
Purpose: We applied Multi-Criteria Decision Analysis (MCDA) methods in a structured benefit-risk assessment of cladribine and newer approved disease-modifying drugs (DMDs) for patients with relapsing-remitting multiple sclerosis (RRMS).
APA:
Vermersch, P., Martinelli, V., Pfleger, C., Rieckmann, P., Alonso-Magdalena, L., Galazka, A.,... Phillips, L. (2019). Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis. Clinical Therapeutics, 41(2), 249-260. https://doi.org/10.1016/j.clinthera.2018.12.015
MLA:
Vermersch, Patrick, et al. "Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis." Clinical Therapeutics 41.2 (2019): 249-260.
BibTeX: Download